1. Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients
- Author
-
Nana Asiedu, Emmanuel Kiiza Mwesiga, Dickens Akena, Corey Morrison, Joy Louise Gumikiriza-Onoria, Angel Nanteza, Juliet Nakku, Nastassja Koen, Noeline Nakasujja, Wilber Ssembajjwe, Christopher M. Ferraris, Anthony F. Santoro, Dan J. Stein, and Reuben N. Robbins
- Subjects
Neurocognitive impairment ,First episode psychosis ,NeuroScreen ,MATRIC consensus cognitive battery ,Uganda ,Low-income country ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Introduction: Neurocognitive impairment (NCI) is commonly exhibited among patients experiencing their first episode of psychosis. However, there are few resources in many low-income countries, such as Uganda, that allow for the administration of extensive neurocognitive test batteries for the detection of NCI. NeuroScreen is a brief tablet-based neurocognitive assessment battery that can be administered by all levels of healthcare staff. We examined the validity of NeuroScreen to assess neurocognition and detect NCI in first-episode psychosis (FEP) patients in Uganda. Methods: We enrolled 112 participants FEP patients and matched controls at Butabika Mental Referral Hospital. Each participant completed NeuroScreen and a traditionally administered neurocognitive battery: the MATRIC Consensus Cognitive Battery (MCCB). We examined correlations between participant performance on NeuroScreen and the MCCB. A ROC curve determined sensitivity and specificity of NeuroScreen to detect NCI as determined by MCCB criterion. Results: There was a large, statistically significant correlation between overall performance on NeuroScreen and the MCCB [r(112) = 0.64, p
- Published
- 2023
- Full Text
- View/download PDF